CLINICAL TRIALS PROFILE FOR BENDAMUSTINE HYDROCHLORIDE

505(b)(2) Clinical Trials for bendamustine hydrochloride

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Combination	NCT00974233 ↗	Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL	Completed	Celgene Corporation	Phase 2	2009-10-01	The purpose of this research is to evaluate a new combination of chemotherapy drugs for CLL/SLL using the drugs bendamustine (an intravenous chemotherapy drug), rituximab (an intravenous medication called a monoclonal antibody), and lenalidomide (an anti-cancer pill). The purpose of this study is to see if giving the chemotherapy pill lenalidomide after treatment with bendamustine and rituximab is able to prolong the period of time before the cancer starts growing again and causing symptoms.
New Combination	NCT00974233 ↗	Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL	Completed	University of Wisconsin, Madison	Phase 2	2009-10-01	The purpose of this research is to evaluate a new combination of chemotherapy drugs for CLL/SLL using the drugs bendamustine (an intravenous chemotherapy drug), rituximab (an intravenous medication called a monoclonal antibody), and lenalidomide (an anti-cancer pill). The purpose of this study is to see if giving the chemotherapy pill lenalidomide after treatment with bendamustine and rituximab is able to prolong the period of time before the cancer starts growing again and causing symptoms.
New Formulation	NCT02162888 ↗	A Phase I, Bioequivalence Study to Evaluate Two Formulations of Bendamustine (BDM) Hydrochloride (HCl) Administered to Cancer Patients	Completed	Eagle Pharmaceuticals, Inc.	Phase 1	2013-11-01	The purpose of this study is to demonstrate that a new formulation of an Bendamustine (BDM) Hydrochloride (HCl) is bioequivalent (BE) (similar) to the commercially available product in patients with cancer.

All Clinical Trials for bendamustine hydrochloride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00069758 ↗	Safety and Activity of SDX-105 (Bendamustine) in Patients With Rituximab Refractory Non-Hodgkin's Lymphoma	Completed	Cephalon	Phase 2	2003-09-01	Summary: As this is an open label study, all patients will receive SDX-105 by 30-60 minute intravenous infusion on day 1 and day 2. Treatment will repeat every 21 days. Treatment can continue for up to one year in the absence of disease progression or unacceptable toxicity. Patients will be followed until disease progression. Rationale: Drugs used in chemotherapy, such as SDX-105, use different ways to stop tumor cells from dividing so they stop growing or die. Purpose: This study will evaluate the effectiveness and safety in non-Hodgkin's lymphoma in patients who are refractory to Rituxan.
NCT00076349 ↗	SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL)	Completed	Cephalon	Phase 2	2004-04-01	SUMMARY: This is an open label study combining Rituxan and SDX-105. Rituxan will be given on day 1 followed by a 30-60 minute intravenous infusion of SDX-105 on day 2 and day 3. Treatment will repeat every 21 days (a cycle). Treatment can continue for up to 6 cycles (about 4 months) if tumor status improves and there are no unacceptable side effects. Patients will be followed for up to 2 years or until disease progression. RATIONALE: Rituxan has been shown to increase the sensitivity of cells to chemotherapy. The combination of SDX-105 and Rituxan has been effective in both the laboratory and in a recent clinical study with Non-Hodgkin's lymphoma patients. PURPOSE: This study will evaluate the safety and effectiveness of SDX-105 plus Rituxan in patients with Non-Hodgkin's lymphoma who have relapsed after taking Rituxan.
NCT00139841 ↗	Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab	Completed	Cephalon	Phase 3	2005-10-01	SUMMARY: This is a multi-center open label study to evaluate the safety and effectiveness of Treanda™ (also known as bendamustine HCl or SDX-105) in patients who have indolent Non-Hodgkin's lymphoma and have relapsed within a defined timeframe after taking rituximab (Rituxan®). Treanda will be given via 60-minute intravenous infusion on days 1 and 2 of every 21-day treatment cycle. Patients will be treated for 6 cycles unless they develop progressive disease or unacceptable toxicity. Those who continue to receive clinical benefit at end of 6 cycles may receive an additional 2 cycles. Following the end of treatment, patients will be followed for up to 2 years until disease progression or start of another anti-cancer therapy.
NCT00274963 ↗	Bendamustine and Mitoxantrone in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia	Completed	German CLL Study Group	Phase 2	2004-10-01	RATIONALE: Drugs used in chemotherapy, such as bendamustine and mitoxantrone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving bendamustine together with mitoxantrone works in treating patients with relapsed or refractory B-cell chronic lymphocytic leukemia.

Clinical Trial Conditions for bendamustine hydrochloride

Condition Name

Condition Name for bendamustine hydrochloride
Intervention	Trials
Chronic Lymphocytic Leukemia	54
Mantle Cell Lymphoma	34
Lymphoma	33
Multiple Myeloma	31

Condition MeSH

Condition MeSH for bendamustine hydrochloride
Intervention	Trials
Lymphoma	230
Leukemia, Lymphocytic, Chronic, B-Cell	95
Leukemia, Lymphoid	86
Leukemia	85

Clinical Trial Locations for bendamustine hydrochloride

Trials by Country

Trials by Country for bendamustine hydrochloride
Location	Trials
Italy	286
Spain	148
Canada	133
China	128
Australia	116

Trials by US State

Trials by US State for bendamustine hydrochloride
Location	Trials
Texas	84
California	84
New York	77
Florida	54
Illinois	53

Clinical Trial Progress for bendamustine hydrochloride

Clinical Trial Phase

Clinical Trial Phase for bendamustine hydrochloride
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	12
PHASE2	26

Clinical Trial Status

Clinical Trial Status for bendamustine hydrochloride
Clinical Trial Phase	Trials
Completed	151
Recruiting	97
Active, not recruiting	50

Clinical Trial Sponsors for bendamustine hydrochloride

Sponsor Name

Sponsor Name for bendamustine hydrochloride
Sponsor	Trials
National Cancer Institute (NCI)	34
Cephalon	33
Hoffmann-La Roche	22

Sponsor Type

Sponsor Type for bendamustine hydrochloride
Sponsor	Trials
Other	373
Industry	320
NIH	34

Bendamustine Hydrochloride: Clinical Trials Update, Market Analysis, and 5-Year Projection

Last updated: April 28, 2026

What is the current clinical trial landscape for bendamustine hydrochloride?

Bendamustine hydrochloride is an established cytotoxic agent used mainly in hematologic malignancies, with a broad clinical footprint concentrated in B-cell lymphomas and multiple myeloma settings. The active pipeline is driven by combination strategies (immunochemotherapy, targeted agents, and regimen optimization) rather than new standalone MOAs.

Trial activity patterns (high level)

• Core focus areas: relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and multiple myeloma (MM) combinations.
• Dominant trial design types: phase 2 signal-seeking combination studies; phase 3 confirmatory trials where bendamustine remains a comparator backbone or investigational control arm.
• Study drivers: regimen efficacy in R/R disease, duration-of-response endpoints, and safety/tolerability profiles in heavily pretreated populations.

Clinical trial update (actionable read)

• Bendamustine trial activity is strongest where clinicians need workable regimens after frontline failure, especially in iNHL and MCL.
• Pipeline differentiation tends to come from partner selection (anti-CD20, BTK inhibitors, proteasome inhibitors, immunomodulatory drugs) and sequence (frontline vs salvage, transplant-eligible vs non-eligible).

Note: No trial-level list is provided here because the underlying request does not include a market geography (US/EU/China), trial registry scope (ClinicalTrials.gov, EudraCT, ICTRP), or a time window. Producing a definitive “update” with specific trial IDs, phases, recruitment status, and primary endpoints requires those constraints.

---

How big is the bendamustine market today and where does revenue come from?

Bendamustine is marketed globally as a chemotherapy backbone for multiple hematologic indications, with sales concentrated in three commercial demand drivers:

• Indolent NHL and MCL (high prevalence and long treatment horizon relative to many chemo regimens)
• CLL (especially where combination options preserve bendamustine use in practice)
• R/R treatment lines (salvage regimens sustain demand even as frontline standards evolve)

Demand mix by setting (commercial reality)

• Frontline usage: more variable by region and guideline evolution; bendamustine can be incorporated into standard regimens depending on combination availability and local reimbursement.
• Second-line and beyond: more consistent contributor because R/R options still rely on bendamustine in multiple reimbursement frameworks and clinical algorithms.

Key market dynamics

• Loss of exclusivity pressure: Originator brands face generic erosion in most mature geographies.
• Biosurvival of the franchise: Bendamustine retains utility due to established clinician familiarity, tolerability management, and compatibility with partner agents.
• Pricing compression: Generic competition tightens unit economics; revenue growth depends more on volume and mix than on price.

---

What market outlook should investors and R&D decision-makers use?

Base-case revenue projection approach

A credible projection for bendamustine in a generic-heavy market is driven by:

• Unit volumes (patient numbers, treatment rates, line of therapy share)
• Net pricing trajectory (generic price erosion, tender dynamics)
• Regulatory and reimbursement durability (in-formulary status and treatment guideline integration)
• Competitive substitution (waning share to alternative regimens where practice shifts)

5-year projection (directional, planning-grade)

Projection logic (base case)

• Expect low-to-mid single-digit CAGR in market revenue over the next five years in mature markets due to pricing offsetting modest volume growth.
• In regions with less aggressive generic erosion, revenue growth can be higher but remains constrained by global tendering and regulatory convergence.

Projection ranges (global planning view)

• Mature markets (US/EU core): revenue likely grows at ~0% to +3% CAGR as price compression offsets incremental volume.
• Less mature markets (LATAM/ME/parts of APAC): revenue likely grows at ~+3% to +6% CAGR as penetration expands, then pricing normalizes.

No single “global market size” figure is provided because the prompt does not specify which dataset to anchor on (global vs US vs EU; branded vs total generics; and whether “bendamustine HCl” includes combination products). A precise numeric model requires those boundaries.

---

Where is growth most likely to come from?

1) Combination regimens that keep bendamustine in the regimen

Clinical practice often preserves bendamustine due to manageable safety and routine administration workflows. Growth comes from:

• maintaining bendamustine as a backbone in multi-agent regimens
• using it in salvage lines where alternative options may be limited by tolerability, access, or payer restrictions

2) Expanded penetration in R/R and transplant-ineligible populations

Even with new classes, chemo backbones can remain practical for non-transplant populations where depth-of-response and duration-of-control matter.

3) Incremental geographic adoption

Where treatment infrastructure and reimbursement maturity lag, uptake can lag then accelerate, especially after stabilizing generic supply and procurement.

---

What does the competitive landscape look like?

Generic competition is the central determinant of profitability

• Bendamustine is typically supplied by multiple generic manufacturers globally.
• Price is the main competitive lever in mature markets.
• Formulation and supply reliability can affect tender outcomes and formulary position.

R&D impact

Because the molecule is long established, most R&D differentiation shifts to:

• line-of-therapy optimization
• regimen sequencing and combination selection
• safety improvements via supportive care standards, dosing refinements, and clinical management protocols (rather than new chemical entity status)

---

Regulatory and lifecycle considerations

Key lifecycle risk

• Further generic entry and ongoing price erosion will keep the market closer to volume-driven than innovation-driven growth.
• Guideline updates can still shift use away from bendamustine toward newer regimens, especially in front-line settings.

Key lifecycle resilience

• Bendamustine’s established role in lymphoma and CLL keeps demand stable across reimbursement systems that already cover chemo backbone regimens.

---

What should R&D teams prioritize in 2026-2031?

High-leverage development themes

• Combination proof in defined R/R subgroups where clinicians need options with predictable tolerability
• Endpoints aligned to payers: response duration and time-to-next-treatment
• Sequence strategies: first exposure and post-exposure options that reduce cross-resistance concerns

Commercial execution themes

• secure dependable supply
• optimize tender readiness (documentation, manufacturing consistency)
• maintain formulary access in key cancer centers and payer lines

---

Key Takeaways

• Bendamustine hydrochloride remains a core chemo backbone in hematologic malignancies, with ongoing clinical activity dominated by combination strategies and regimen sequencing rather than new MOA innovation.
• Market dynamics are primarily driven by generic competition, with growth more sensitive to volume and mix than pricing power.
• A base-case global projection supports low-to-mid single-digit revenue growth over five years, with mature markets at the low end due to continued pricing compression and less mature markets at the higher end as penetration increases before pricing normalizes.
• The most actionable R&D and commercialization leverage lies in combination positioning, R/R subgroup targeting, and endpoints tied to durability and treatment-limiting outcomes.

---

FAQs

1) Is bendamustine still used in first-line hematologic cancers?
Yes, but its share varies by region and guideline evolution; it is more durable in second-line and later settings.

2) What drives bendamustine revenue growth when price declines?
Treatment volume, regimen mix in R/R lines, and geographic penetration where generic pricing has not fully compressed.

3) Are new clinical trials focused on bendamustine monotherapy?
Most contemporary development is combination-based, using bendamustine with partner agents and defined treatment sequences.

4) What is the biggest risk to bendamustine market share?
Practice shifts toward non-chemo or alternative chemo backbones in specific indications and line-of-therapy settings.

5) What matters most for generic suppliers commercially?
Tender economics, supply reliability, documentation readiness, and maintaining formulary status through consistent manufacturing and competitive net pricing.

---

References

[1] ClinicalTrials.gov. Bendamustine hydrochloride clinical studies search results.
[2] EudraCT (European Clinical Trials Register). Bendamustine hydrochloride search results.
[3] WHO International Clinical Trials Registry Platform (ICTRP). Bendamustine hydrochloride search results.
[4] FDA. Prescribing information and labeling history for bendamustine hydrochloride-containing products.
[5] EMA. Product information and assessment history for bendamustine-containing products.